Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Organogenesis Holdings Inc.NASDAQ: ORGO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$56.1M, compared with -$19.5M a year earlier. Trailing-twelve-month EBITDA was $37.31M. Over 3 fiscal years it compounded at +22.4% a year.

Context

  • EBITDA amounted to 13.1% of revenue in FY2025, up 9.9 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of -$161.63M (-318.7%) for the fiscal year ending Dec 2026, a slowdown from the +368.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$56.1M-179.6% QoQ
Last fiscal yearDec 2025
$73.91M+368.9% YoY
LTMMar 2026
$37.31M+1061.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-187.7%-644.5%-456.8 pp
1 year+368.9%-318.7%-687.6 pp
3-year CAGR+22.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
73.91M USD
Year-over-year change
+368.9%
4-year CAGR
-4.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ORGO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1061.2% is the highest of 11, against a peer median of +2.4%.
  • EBITDA amounts to 7.3% of revenue for ORGO, versus a peer median of 7.4%.
ORGO Competitors
EBITDA for ORGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$154.5M USD+28.1%+148.3%22.8%
SNDLSNDL Inc.LTM Mar 2026CA$49.42M CAD+201.3%—5.3%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$39.9M USD+145.1%—9.5%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$37.31M USD+1061.2%+22.4%7.3%
SIGASIGA Technologies, Inc.LTM Mar 2026$27.5M USD-56.2%-11.5%29.3%
ANGOAngioDynamics, Inc.LTM Feb 2026-$5.44M USD-1089.6%-46.2%1.7%
VREXVarex Imaging CorporationLTM Apr 2026-$6.2M USD-108.2%-68.7%0.7%
EOLSEvolus, Inc.LTM Mar 2026-$14.03M USD+53.2%—4.6%
MNPRMonopar Therapeutics Inc.LTM Mar 2026-$15.64M USD+5.6%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$67.05M USD-25.2%——
BCYCBicycle Therapeutics plcLTM Mar 2026-$211.5M USD-0.8%—333.1%
Peer median (excluding ORGO) —+2.4%-28.8%7.4%

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue467.36M450.89M433.14M482.04M563.03M
Cost of Revenue114.2M105.02M106.48M115.74M137.52M
Gross Profit353.16M345.87M326.66M366.3M425.51M
Gross Margin75.6%76.7%75.4%76.0%75.6%
Research & Development30.74M39.76M44.38M50.27M44.54M
Selling, General & Admin250.2M283.81M269.75M294.51M326.24M
Operating Expenses280.94M323.57M314.13M367.59M369.64M
Depreciation & Amortization16.68M18.03M23.45M17.03M26.94M
EBITDA87M40.32M36.03M15.76M73.91M
EBITDA Margin18.6%8.9%8.3%3.3%13.1%
Operating Income72.22M22.3M12.53M(1.28M)55.87M
Operating Margin15.5%4.9%2.9%-0.3%9.9%
Interest Income00002.28M
Interest Expense7.24M2.01M2.19M1.54M0
Other Income / Expenses(9.13M)(2.02M)(2.13M)(1.52M)(8.9M)
Income Before Tax63.09M20.28M10.39M(2.81M)46.97M
Pre-Tax Margin13.5%4.5%2.4%-0.6%8.3%
Income Tax Expense(31.12M)4.75M5.45M(3.67M)9.94M
Net Income94.2M15.53M4.95M861K37.03M
Net Margin20.2%3.4%1.1%0.2%6.6%
EPS (Basic)0.730.120.04(0.01)0.16
EPS (Diluted)0.700.120.04(0.01)0.15
Weighted Avg Shares128.33M130.07M131.23M131.67M126.74M
Weighted Avg Shares (Diluted)133.66M132.38M132.75M131.67M130.25M

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.